Hercules Capital

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing novel therapies for inflammatory skin and joint diseases. Its flagship product, SLK, is an investigational Nanobody targeting IL-17A and IL-17F, showing potential for disease modification in dermatology and rheumatology patients.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Job&Talent is a global marketplace connecting skilled professionals with reputable companies. Leveraging advanced technology, it facilitates reliable and flexible job placements, benefiting both employees seeking opportunities and businesses requiring agile workforces.

Remodel Health is a technology company that specializes in employee health benefits. It offers a user-friendly software platform that assists businesses in transitioning to Individual Coverage Health Reimbursement Arrangements (ICHRA), providing more tailored and cost-effective health benefits to their employees. The platform simplifies the process for employers and brokers, helping businesses of all sizes retain employees by offering personalized health benefits solutions.

Founded in 2012, Omio operates a multi-modal travel platform that enables users to compare, plan, and book various modes of transportation including trains, buses, flights, and hotels. The platform uses real-time data to suggest optimal routes, estimate travel time, and provide cost comparisons across different travel options.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Behavox provides a unified enterprise platform that combines various data types into a single data lake. This enables real-time querying of data and application of machine learning to identify misconduct, insider threats, and other risks in capital markets. The company's software is designed for large-scale deployment at major financial institutions, offering sophisticated engineering solutions based on cutting-edge academic research.

Smartsheet Inc. is a cloud-based platform designed for effective work execution, enabling organizations to manage projects, programs, and processes with enhanced efficiency. Founded in 2005 and headquartered in Bellevue, Washington, Smartsheet provides a range of collaborative tools tailored to various business needs. Its offerings include Smartdashboards for real-time visibility, Smartportals for easy access to project resources, Smartcards for workflow organization, and Smartgrids for tracking multiple tasks. The platform also features Smartprojects for team collaboration, Smartcalendars for aligning deadlines, Smartforms for structured information collection, and Smartautomation for process automation. Additionally, Smartsheet integrates with existing enterprise applications, facilitating seamless operations across diverse sectors such as aerospace, healthcare, finance, and technology. The company generates revenue through software subscriptions and additional charges for enhanced platform capabilities.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Thumbtack is an online services marketplace that connects homeowners with local professionals across categories including movers and packers, contractors, plumbers, roofers, cleaners, handymen, attorneys, web designers, application developers, personal trainers, electricians, landscapers, and photographers. It provides personalized guidance on what to do and when to do it, and recommendations on who to hire from a large community of service providers, enabling homeowners to manage and complete home projects by hiring the right professionals. Founded in 2008 and based in San Francisco, Thumbtack helps users plan, manage, and execute home improvement, repair, and everyday service needs.

Pindrop specializes in voice-driven security and intelligence solutions for enterprises. It leverages unique audio analysis technology to authenticate calls, detect fraud, and enhance customer experiences across various industries.

NeueHealth is a healthcare company dedicated to providing high-quality, coordinated care to aging and underserved populations. It operates through two segments: NeueCare, which manages risk in partnership with external payors, serving diverse patient populations; and NeueSolutions, offering technology, services, and clinical care solutions to empower providers.

Semperis develops an identity‑focused cybersecurity platform that protects the integrity and availability of enterprise directory services. Its suite enables organizations to automatically restore an entire Active Directory forest, recover thousands of objects or individual attributes, and revert to a previous state after accidental or malicious changes. The platform also offers real‑time attribute search, comparison, and restoration, hybrid threat detection, incident response, disaster recovery, and tools for Active Directory migration and consolidation. Additional capabilities include security posture assessment and attack path discovery within an identity resilience framework. Founded in 2013–2014, the company is headquartered in Hoboken, New Jersey, with offices in New York and Ramat Gan, and serves Fortune 500, financial, healthcare, and government customers worldwide.

Adaptimmune Therapeutics is a biopharmaceutical company focused on developing novel cell therapies to treat solid tumors. It employs its proprietary SPEAR T-cell platform to identify cancer targets and generate therapeutic candidates for clinical trials.

Harness is a software company that provides a continuous delivery-as-a-service platform designed to automate and streamline the end‑to‑end software development lifecycle. Leveraging artificial intelligence and machine learning, the platform offers AI‑driven pipeline automation, real‑time delivery analytics, automated verification, intelligent testing, security orchestration, and cloud cost management. It supports modern cloud environments, containers, and orchestration tools such as Kubernetes and Amazon ECS, enabling engineering and DevOps teams to accelerate deployment cycles, reduce manual effort, and improve software reliability. Founded in 2015 and headquartered in San Francisco, the company focuses on simplifying the process of moving code from artifact to production.

Electric Hydrogen is a company focused on deep decarbonization by developing low-cost, high-efficiency systems for producing fossil-free hydrogen. The company targets industrial sectors such as ammonia and steel production, which contribute significantly to global greenhouse gas emissions. By rethinking electrolysis technology from scratch, Electric Hydrogen aims to make clean hydrogen competitive with traditional methods in terms of cost and scale. Their advanced PEM (Proton Exchange Membrane) technology uses renewable electricity to generate clean hydrogen gas, reducing industrial pollution and dependence on fossil fuels. The company's leadership team brings extensive experience from pioneering clean energy companies like Tesla and First Solar, positioning Electric Hydrogen as a strong contender in the quest for zero-emission industrial processes.

SynOx Therapeutics is a biopharmaceutical company focused on developing emactuzumab, a monoclonal antibody targeting CSF-1R, for treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Incorporated in 2019, the company is based in Dublin, Ireland.

Bluebird Bio is a clinical-stage biotechnology company focused on developing gene therapies to treat severe genetic and rare diseases. Its proprietary lentiviral vector platform enables the creation of potentially curative treatments by genetically modifying patients' cells to address the root cause of these conditions.

Reveleer is a healthcare software and services company that operates a Software-as-a-Service analytics platform focused on medical record analysis and targeted solutions. Founded in 2009 and based in Glendale, California, the company enables payers across Medicare, Medicaid, and commercial sectors to effectively manage risk adjustment and quality improvement programs. Reveleer's platform provides a comprehensive suite of services, including medical record collection, retrieval, coding, and abstraction, all integrated into a single system. Additionally, the company offers professional services such as abstractor training, auditing, and strategic assessments to enhance operational practices and data management. Formerly known as Health Data Vision, Inc., Reveleer rebranded in August 2019 to reflect its commitment to empowering healthcare organizations to take control of their data and improve coding accuracy.

Sight Sciences, Inc. is a medical device company specializing in the development and commercialization of technologies for the treatment of eye diseases, particularly glaucoma and dry eye conditions. Headquartered in Menlo Park, California, with an additional office in Southlake, Texas, the company offers the OMNI Surgical System, which allows surgeons to perform canaloplasty and trabeculotomy through a single device and corneal incision, thereby reducing intraocular pressure in patients with primary open-angle glaucoma. Additionally, Sight Sciences provides the TearCare System, a wearable eyelid technology that delivers targeted and adjustable thermal energy to the meibomian glands, addressing conditions like meibomian gland dysfunction and dry eye. Founded in 2010, the company aims to improve patient outcomes through innovative approaches in ophthalmic care.

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for chronic respiratory diseases with unmet medical needs. Its lead candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterases 3 and 4 that provides bronchodilation and anti-inflammatory effects in a single molecule. Development programs include formulations of ensifentrine for chronic obstructive pulmonary disease, with options such as nebulized administration, a dry powder inhaler, and a pressurized metered-dose inhaler. Verona Pharma is also pursuing development of ensifentrine for cystic fibrosis and asthma. The company was founded in 2005 and is headquartered in London, United Kingdom.

Shield AI Inc is an artificial intelligence robotics company based in San Diego, California, focused on developing advanced AI-powered systems for national security and first responders. Incorporated in 2015, the company specializes in creating technologies that enhance the safety of military personnel and civilians. Its flagship products include Nova, an autonomous quadcopter drone equipped with lidar technology that operates effectively in GPS-denied environments, and Hivemind, an AI framework that allows various unmanned vehicles to learn from real and synthetic experiences, enabling autonomous operations without direct human control. Additionally, Shield AI has developed the V-BAT, a vertical takeoff and landing aircraft that can navigate contested environments and has been utilized in regions like the Black Sea and the Middle East. The company aims to transform defense operations by leveraging cutting-edge AI and machine learning technologies to execute complex tasks in dynamic and denied environments.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Vida Health is a virtual care platform focused on whole health by treating mental and physical conditions together. The platform combines an AI-powered, personalized experience with human coaches and therapists, offering video sessions, messaging, and digital content to help people prevent, manage, and reverse chronic conditions such as diabetes and hypertension, along with associated mental health conditions like stress, depression, and anxiety. The company serves large employers and health plans, providing access to clinicians including nutritionists, diabetes educators, nurses, trainers, and licensed therapists.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

Eat Just, Inc., founded in 2011 and based in San Francisco, California, focuses on creating plant-based food products aimed at improving the food system. The company offers a variety of items, including plant-based scrambled eggs, flavored mayonnaise, dressings, cookie doughs, and meat alternatives. Their flagship product, JUST Egg, has garnered significant recognition, being featured in lists such as Popular Science's "100 Greatest Innovations." Eat Just emphasizes innovation through a unique discovery platform for food ingredients, combining scientific research with culinary expertise from Michelin-starred chefs. The company has been acknowledged in various prestigious lists, including Fast Company’s "Most Innovative Companies" and Entrepreneur’s "100 Brilliant Companies."

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

Heron Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative treatments to address unmet medical needs. The company utilizes its proprietary Biochronomer drug delivery technology, which enables sustained release of therapeutic agents over days to weeks with a single administration. Heron's product portfolio includes SUSTOL, an extended-release injection for preventing nausea and vomiting associated with chemotherapy, and CINVANTI, an intravenous formulation for similar indications. Additionally, the company is advancing HTX-011, a dual-acting combination of bupivacaine and meloxicam, currently in Phase III clinical trials for pain management, and HTX-034, aimed at postoperative pain relief. Founded in 1983, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

COMPASS Pathways is a UK-based mental health care company dedicated to accelerating patient access to innovative treatments for mental health challenges. The company focuses on developing psilocybin therapy, administered in conjunction with psychological support, for patients with treatment-resistant depression who have not responded to conventional treatments.

Tipalti, Inc., established in 2010, specializes in accounts payable automation and global mass payments. Headquartered in San Mateo, California, with an additional office in Israel, the company offers a comprehensive software solution that streamlines and automates the process of paying suppliers, partners, and publishers worldwide. Tipalti's platform covers all aspects of the payables workflow, including supplier onboarding, invoice processing, global funds disbursement, tax compliance, and payment reconciliation. By utilizing Tipalti, businesses can significantly reduce their supplier payment workload, strengthen financial controls, ensure regulatory compliance, and improve partner payment experiences, enabling them to focus on strategic growth.

Skydio designs, manufactures, and supports AI-powered drones for consumers, enterprises, and government customers. Its drones use computer vision technology to recognize, avoid objects in real-time, and predict future movements, enabling autonomous flight and obstacle avoidance.

Founded in 2021, AmplifyBio is a biotechnology company headquartered in West Jefferson, OH. It specializes in developing next-generation cell and gene therapies, with a mission to advance medical breakthroughs and treatments for diseases.

Founded in 2014, Locus Robotics develops autonomous mobile robots (AMRs) for fulfillment warehouses. Its flagship product, LocusBots, collaborates with human workers to enhance order productivity and accuracy by up to threefold, serving retailers, manufacturers, and logistics providers.

Oak Street Health, Inc. is a healthcare provider that operates a network of primary care centers specifically designed to serve Medicare beneficiaries in medically underserved communities across the United States. Founded in 2012 and headquartered in Chicago, Illinois, the company prioritizes a value-based care model over a volume-based approach, emphasizing comprehensive preventive care. Oak Street Health offers personalized wellness plans, integrated health services, and educational and social activities aimed at improving health outcomes for older adults while also lowering medical costs. As of September 2020, it operated 67 centers in various states, including Illinois, Indiana, and Texas, addressing the significant gap in quality healthcare available to its target population.

Kura Oncology is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for cancer patients. Its pipeline comprises small molecule drug candidates targeting specific cancer signaling pathways, with a focus on solid tumors and hematologic malignancies.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.

Bright Machines, Inc. is a manufacturing company that specializes in robotic arms and cells for micro factories, focusing on the assembly and inspection of products. Founded in 2018 and headquartered in San Francisco, California, with additional offices in Tel Aviv, China, and Mexico, the company combines robotics and advanced software to enhance manufacturing processes. Its software-defined manufacturing platform utilizes artificial intelligence and machine learning to create adaptable, sensor-rich robots with computer vision capabilities. This innovative approach aims to reduce reliance on manual labor and help businesses meet the increasing demands of modern manufacturing, ultimately improving yields while lowering costs.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, established in 2013. The company specializes in the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a common complication of CKD, can accelerate kidney deterioration and is associated with serious health risks, including muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, positioning the company to address a significant unmet medical need in CKD management through the innovative approach of binding and removing acid from the gastrointestinal tract.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Automation Anywhere, Inc. is a global leader in Robotic Process Automation (RPA), specializing in the development of AI-powered software solutions designed to enhance business efficiency. Founded in 2003 and headquartered in San Jose, California, the company offers a cloud-native platform that integrates RPA with artificial intelligence, machine learning, and analytics. Its flagship products include Automation Anywhere Enterprise, which automates IT and business processes; Automation Anywhere Server for streamlined business operations; and IQ Bot, a cognitive automation solution that addresses complex business tasks. Additionally, the company provides a comprehensive suite of testing tools, such as Testing Anywhere, which supports quality assurance across various platforms. Automation Anywhere also offers consulting services and collaborates strategically with Microsoft Azure. The company has expanded its presence internationally with offices in several major cities across the United States, Europe, the Middle East, and Asia.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company based in Oldwick, New Jersey, focused on developing and commercializing innovative therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's pipeline includes several product candidates, such as PRV-031 teplizumab, which is in Phase III trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor currently in Phase IIa trials for Crohn's disease. Additional candidates include PRV-3279 for lupus, PRV-101, a vaccine for coxsackie virus B infections, and PRV-015, an anti-IL-15 monoclonal antibody in Phase IIb trials for non-responsive celiac disease. Provention Bio's approach aims to reduce the burden of chronic autoimmune and inflammatory diseases through early intervention. The company was incorporated in 2016 and is committed to leveraging its expertise in translational medicine and immunology to efficiently develop and partner with clinical-stage assets.

Alladapt Immunotherapeutics is a privately held biopharmaceutical company focused on developing prescription therapeutics for food allergy. Based in Menlo Park, California, it was founded in 2018. The company’s lead program, ADP101, is a broad-spectrum oral immunotherapy designed to mitigate, treat, and prevent reactions to foods by targeting single or multiple allergen proteins across common allergens.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatments for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. By focusing on these areas, IVERIC bio aims to address critical gaps in the current treatment landscape for patients suffering from various retinal conditions.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

Geron Corporation is a late-stage clinical biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of therapeutics for hematologic malignancies. Established in 1990, the company is primarily focused on its investigational drug, imetelstat, a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. Imetelstat targets the uncontrolled proliferation of malignant progenitor cells, aiming to improve blood cell production in patients with conditions such as myelodysplastic syndromes and myelofibrosis. Geron generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements, positioning itself as a key player in oncology therapeutics.

Akero Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, with a primary emphasis on nonalcoholic steatohepatitis (NASH). Its lead program is a long-acting fibroblast growth factor 21 (FGF21) analog designed to restore metabolic balance and address liver fat, inflammation, and fibrosis. The company was founded in 2017 and is headquartered in South San Francisco, California.

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic and liver diseases, including cardiovascular-metabolic conditions and metabolic dysfunction-associated steatohepatitis. The company’s lead drug, resmetirom, is an oral liver-directed thyroid hormone receptor beta agonist advancing in late-stage trials for non-alcoholic steatohepatitis. Madrigal is pursuing additional THR-beta agonists in preclinical development to address NASH and related dyslipidemia, and maintains collaborations to develop and commercialize licensed products, including with Hoffmann-La Roche. The company targets broader cardiovascular-metabolic diseases such as diabetes and dyslipidemia. Founded in 2011, Madrigal is headquartered in West Conshohocken, Pennsylvania.

Convoy operates an online marketplace for digital freight network services. It connects shippers with local and regional trucks for moving goods efficiently, offering real-time tracking via its mobile app. Founded in 2015, Convoy aims to optimize the trucking industry by reducing waste and emissions.

Viridian Therapeutics is a biotechnology company dedicated to developing treatments for patients with underserved diseases. Its primary focus is on thyroid eye disease, a debilitating orphan condition, using product candidates such as Veligrotug.

Carwow is an online platform that connects car buyers directly with dealerships, facilitating transparent comparisons of offers on configured cars. It provides comprehensive buying advice and enables seamless transactions between consumers and official dealers.

Esme Learning Solutions LLC, based in Charlestown, Massachusetts, specializes in online learning solutions for executives and working professionals. It delivers transformational learning experiences through video conference calls and online programs, supporting individual learners, universities, and corporations. The company's AI-based platform offers personalized courses in emerging fields like blockchain and fintech, enabling users to design engaging online teaching programs for time-pressed executives.

Lucira Health, Inc. is a medical technology company that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013 and based in Emeryville, California, Lucira has created a consumer-friendly, single-use testing platform that delivers centralized-laboratory-accurate molecular testing. Their flagship product is a disposable COVID-19 test kit that can be used at home, featuring a mobile application that connects users to treatment options. The kit is powered by two AA batteries and is compact enough to fit in the palm of a hand. Additionally, Lucira has developed a 2-in-1 lab testing solution that can determine if viral respiratory symptoms are due to COVID-19 or the flu, enhancing the accessibility and convenience of viral testing for consumers.

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. Its lead therapies include Umbralisib (PI3K delta and CK1 epsilon inhibitor) for NHL and CLL, Ublituximab (CD20-targeting antibody) for NHL, CLL, and MS, Cosibelimab (PD-L1 inhibitor), TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific antibody). The company has strategic alliances with several pharmaceutical companies and generates revenue primarily in the United States.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Carwow is an online platform that connects car buyers directly with dealerships, facilitating transparent comparisons of offers on configured cars. It provides comprehensive buying advice and enables seamless transactions between consumers and official dealers.

FTX is a cryptocurrency exchange company that develops platforms for professional trading firms, offering intuitive interfaces suitable for both experienced traders and beginners. It supports quarterly and perpetual futures for all major cryptocurrencies, leveraged tokens, and OTC derivatives.

Locus Biosciences is a biotechnology company focused on developing a CRISPR-engineered precision antibacterial platform aimed at transforming the treatment of bacterial diseases. The company integrates the antibacterial capabilities of CRISPR-Cas3 technology with the effective and safe delivery of bacteriophages, which are viruses that specifically target bacteria. This innovative approach allows for rapid initiation of treatment by physicians, leading to improved medical outcomes for patients. Through its advanced platform, Locus Biosciences seeks to address the challenges posed by pathogenic bacteria in a precise and targeted manner.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Corium International specializes in the development, manufacture, and commercialization of transdermal and transmucosal drug delivery systems for various therapeutic areas. Its product portfolio includes treatments for hypertension, chronic pain, teeth whitening, osteoporosis, Alzheimer's disease, psychiatric disorders, Parkinson's disease, and motion sickness. The company focuses on enhancing therapeutic profiles and improving patient outcomes through its proprietary technologies.

3Gtms, Inc. is a provider of multi-modal transportation management software solutions designed for shippers, logistics service providers, carriers, third-party logistics providers, freight brokers, and freight auditors. Founded in 2010 and headquartered in Shelton, Connecticut, with additional offices in Raleigh, North Carolina, Utrecht in the Netherlands, and Wayne, Pennsylvania, the company offers a comprehensive Transportation Management Suite that encompasses the entire transportation lifecycle, including rating, routing, tendering, tracking, and settlement. 3Gtms also features specialized solutions such as the Contract Management Suite and the LTL Rate Management Suite, which provide innovative alternatives to traditional rating tools. The company's cloud-based and on-premise offerings are complemented by support, training, and consulting services. 3Gtms has established a strategic alliance with Trimble, further enhancing its capabilities in transportation management.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.

Better Therapeutics is a prescription digital therapeutics company focused on discovering, developing, and commercializing software-based solutions for cardiovascular and metabolic diseases. The company employs clinically-validated, FDA-regulated software to provide digital behavioral therapy aimed at altering the behaviors that contribute to these diseases. This approach is designed to enhance patients' quality of life, reduce reliance on medications, and lower healthcare costs. Better Therapeutics integrates neuroscience, lifestyle medicine, and explainable artificial intelligence into a mobile medical app that is prescribed by physicians. This app utilizes patient-generated data to guide clinical decision-making and improve treatment outcomes. Currently, the company's product pipeline includes therapeutic candidates targeting type 2 diabetes, hypertension, and dyslipidemia.

Novelion Therapeutics Inc. is a biopharmaceutical company based in Vancouver, Canada, focused on developing therapies for individuals with rare diseases. The company offers commercial products, including metreleptin, which treats complications of leptin deficiency in patients with generalized lipodystrophy, marketed under the MYALEPTA brand, and lomitapide capsules for adult patients with homozygous familial hypercholesterolemia, sold as JUXTAPID and LOJUXTA. Novelion also invests in the development of innovative therapies, including zuretinol acetate for treating inherited retinal diseases linked to mutations in specific genes. Originally founded in 1981 as QLT Inc., the company rebranded to Novelion Therapeutics in 2016 and operates through its subsidiary, Aegerion Pharmaceuticals, which is dedicated to addressing the needs of patients with debilitating rare diseases.

Founded in 2019, HiberCell is a biotechnology company based in New York. It develops therapeutics focused on preventing cancer relapse and metastasis by targeting adaptive stress pathways and immune modulation.

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies for fungal infections in the United States and internationally. Its lead product candidate, ibrexafungerp, is being developed as both an oral and intravenous treatment for various fungal infections, including vulvovaginal candidiasis and invasive aspergillosis. Ibrexafungerp has successfully completed Phase 2 clinical trials for its indication in vulvovaginal candidiasis. The company collaborates with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to advance the development and commercialization of ibrexafungerp. In addition to its antifungal focus, SCYNEXIS engages in drug discovery and development across multiple therapeutic areas, including antibacterials and oncology, and offers contract research solutions such as medicinal chemistry and process development. Originally founded in 1999 and known as SCYNEXIS Chemistry & Automation, Inc., the company rebranded to SCYNEXIS, Inc. in June 2002 and is headquartered in Jersey City, New Jersey.

Plaid is a technology platform that provides APIs and developer tools to connect consumer bank accounts and financial data with applications. It enables developers to build modern financial services by offering infrastructure and intelligence tools that allow access to transactions, authentication for bank accounts, identity verification, real-time balances, asset verification, and income data. Its products include Transactions, Auth, Identity, Balance, Assets, and Income, supporting personal finance, consumer payments, lending, banking and brokerage, and business finance solutions. Plaid serves developers from startups to large financial institutions, helping democratize financial services with a developer-friendly experience. The company was founded in 2012 and is headquartered in San Francisco, California.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

Raydium is an automated market maker (AMM) operating on the Solana blockchain. It leverages the central order book of Serum DEX to facilitate swift trades and shared liquidity, offering users new ways to earn yield.

SingleStore is a data technology company that provides a distributed SQL database platform designed for real-time transactions and analytics. Its offerings include SingleStore DB, a distributed SQL database that can run on bare metal, in the cloud, or in hybrid deployments for operational analytics, and SingleStore Managed Service, a cloud database-as-a-service that provides analytics across a cloud of choice. The platform combines transactional and analytical processing in a single engine, supports real-time querying, multi-model data, and scalable ingestion, and aims to modernize data platforms, secure workloads, and support customer analytics across industries such as financial services, media and communications, energy and utilities, government, retail, and technology. Headquartered in San Francisco with additional offices, the company serves global enterprises by enabling real-time insights from data.

CloudBolt Software operates a cloud management platform that enables enterprise IT departments to function as cloud service providers. Its flagship product, CloudBolt, integrates on-premises resources and public clouds into a single interface, empowering end-users with self-service applications and environments. The company also offers OneFuse for codeless integration and Kumolus for optimizing public cloud usage. Serving enterprises across various industries, CloudBolt Software helps manage hybrid/multi-cloud environments, user self-service, cost management, and replaces vRA/vCAC.

Udacity, established in 2011, is a Mountain View, California-based online learning platform that specializes in providing industry-relevant skills training. It offers a range of nanodegree programs in areas such as artificial intelligence, machine learning, data science, and cloud computing, among others. Udacity's courses are designed to equip learners with the skills that employers value, and its credentials are endorsed by industry partners. The company aims to make education accessible and affordable, with a mission to help students worldwide secure the jobs they desire. Udacity has raised over $163 million from investors, including Andreessen Horowitz and GV, and is valued at over $1 billion.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

SingleStore is a data technology company that provides a distributed SQL database platform designed for real-time transactions and analytics. Its offerings include SingleStore DB, a distributed SQL database that can run on bare metal, in the cloud, or in hybrid deployments for operational analytics, and SingleStore Managed Service, a cloud database-as-a-service that provides analytics across a cloud of choice. The platform combines transactional and analytical processing in a single engine, supports real-time querying, multi-model data, and scalable ingestion, and aims to modernize data platforms, secure workloads, and support customer analytics across industries such as financial services, media and communications, energy and utilities, government, retail, and technology. Headquartered in San Francisco with additional offices, the company serves global enterprises by enabling real-time insights from data.

ZeroFOX is a cybersecurity company that provides external threat intelligence and protection against social media–based threats. It operates a cloud-based platform delivering real-time social threat analytics, protection, and monitoring to safeguard brands, people, and data across the public attack surface. Its solutions address phishing, credential compromise, impersonation, information leakage, brand hijacking, and physical or reputational risks to executives and high-profile individuals, with services including managed monitoring and protection. The company supports industries such as financial services, retail, government, healthcare, technology, education, media, and sports, and offers specialized protections for elections and high-value personnel.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory disorders, autoimmune diseases, and cancer. It focuses on orally-administered small molecule therapeutics targeting chemokine receptors.

Dashlane is a credential manager and digital identity solution that secures passwords, payments, and personal data across devices. The platform stores and manages passwords, autofills forms, and enables secure logins and online purchases with minimal input. It includes a digital wallet to capture receipts and manage purchases, and provides security features for individuals as well as business offerings such as Dashlane Business 2.0 to reduce insecure password sharing. Additional tools, including Inbox Security Scan for mobile users, support an integrated approach to digital security and identity management. Founded in 2009, Dashlane is based in New York with offices in Paris and Lisbon, serving more than 19 million users and more than 22,000 businesses worldwide.

Aldeyra Therapeutics is a biotechnology company focused on developing and commercializing next-generation medicines to address immune-mediated and metabolic diseases. Its lead program Reproxalap is in late-stage development for dry eye disease and allergic conjunctivitis, with additional candidates targeting retinal and systemic inflammatory conditions. The company maintains a broader portfolio that includes compounds such as ADX248, ADX743, ADX631, ADX246, ADX629, and ADX2191, and is exploring therapies for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, Sjögren-Larsson Syndrome, other retinal diseases, autoimmune diseases, and cancer.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

FuelCell Energy designs, manufactures, sells, installs, operates, and services stationary fuel cell power plants for distributed power generation. Its products generate electricity and usable heat, serving utilities, industries, municipalities, and various other sectors. The company focuses on decarbonizing energy strategies and offers solutions for ultra-clean energy while supporting net-zero commitments.

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. Its lead therapies include Umbralisib (PI3K delta and CK1 epsilon inhibitor) for NHL and CLL, Ublituximab (CD20-targeting antibody) for NHL, CLL, and MS, Cosibelimab (PD-L1 inhibitor), TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific antibody). The company has strategic alliances with several pharmaceutical companies and generates revenue primarily in the United States.

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for urologic conditions. Its lead product candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH), and pain associated with irritable bowel syndrome (IBS). The company's second investigational product candidate, URO-902, is a novel gene therapy for patients with OAB symptoms who have failed oral pharmacologic therapy.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Mesoblast develops and commercializes allogeneic cellular medicines derived from its proprietary mesenchymal lineage adult stem cell platform. Its product pipeline focuses on areas such as cardiovascular diseases, orthopedic disorders, oncology, hematology, and immune-mediated conditions. Key products include Ryoncil for steroid-refractory acute graft versus host disease and Revascor for chronic heart failure.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

Contentful is a cloud-based content platform that unifies and structures content in a single hub for web and mobile applications, enabling digital experiences at scale across multiple channels. It provides an extensible framework with open APIs that allow seamless integration with hundreds of tools, supporting developers in building and reusing content components, templates, and design elements across properties. The platform is used by digital-first businesses and a diverse set of brands to accelerate content delivery and maintain on-brand experiences. Contentful was founded in 2011 and is headquartered in Berlin, with offices in San Francisco and Denver.

Founded in 1993, Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on discovering, designing, and developing therapies for diseases, particularly in the areas of autoimmunity and cancer.

Acacia Pharma is a pharmaceutical company dedicated to discovering and developing supportive care drugs. Its primary focus is on cancer supportive care, with products including BAREMSIS for post-operative nausea and vomiting, APD403 for chemotherapy-induced nausea and vomiting, and BYFAVO for sedation during invasive medical procedures. The company serves anesthesiologists and oncologists, aiming to improve the care of patients undergoing serious medical treatments.

Asensus Surgical is a medical device company focused on enhancing minimally invasive surgery through digital laparoscopy. By digitizing the interface between surgeons and patients, the company incorporates advanced technologies such as augmented intelligence, connectivity, and robotics into surgical procedures. Their flagship product, the Senhance Surgical System, is notable for being the first machine vision system designed for robotic surgery. This system is supported by the Intelligent Surgical Unit, which facilitates augmented intelligence in surgery. Asensus Surgical aims to address various clinical, cognitive, and economic challenges faced in surgical practices, ultimately improving patient outcomes through innovative solutions in digital laparoscopy.

CloudPay is a provider of managed global payroll services tailored for multinational organizations, utilizing a single, unified SaaS platform. The company specializes in delivering end-to-end payroll solutions that ensure accurate and compliant payroll processing across over 130 countries and in more than twenty-five languages. By standardizing payroll functions across various geographies, CloudPay enhances operational efficiency, facilitates compliance, and offers greater visibility into payroll performance and costs. With over twenty years of industry experience and a client base of more than 2,500 multinational entities, CloudPay has earned recognition for its innovative technology and services, receiving multiple awards including accolades for Global Payroll Transformation and Payroll Software Product of the Year.

RumbleON is an online retailer that enables consumers and dealers to buy, sell, trade, and finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience. It specializes in Harley-Davidson bikes and related recreational vehicles, leveraging e-commerce to facilitate acquisitions and transactions across the motorcycle market.

Dashlane is a credential manager and digital identity solution that secures passwords, payments, and personal data across devices. The platform stores and manages passwords, autofills forms, and enables secure logins and online purchases with minimal input. It includes a digital wallet to capture receipts and manage purchases, and provides security features for individuals as well as business offerings such as Dashlane Business 2.0 to reduce insecure password sharing. Additional tools, including Inbox Security Scan for mobile users, support an integrated approach to digital security and identity management. Founded in 2009, Dashlane is based in New York with offices in Paris and Lisbon, serving more than 19 million users and more than 22,000 businesses worldwide.

Metalysis Limited is a technology company based in Rotherham, United Kingdom, specializing in the manufacture of high-value metals and alloys, including titanium and tantalum. Established in 2001, the company has developed a solid-state process for producing metal alloy powders, which are primarily utilized in advanced manufacturing, aerospace, and automotive sectors. This innovative process, originally conceived at The University of Cambridge, offers a more environmentally friendly and energy-efficient alternative to conventional melting methods. Metalysis focuses on creating 3D printable metal powders and niche, high-performance alloys, catering to the needs of various industries. The company is advancing its production capabilities through its Generation 4 technological expansion, aiming to scale up its manufacturing processes.

Gibraltar Business Capital, LLC, based in Northbrook, Illinois, provides working capital solutions to small and medium-sized businesses across various industries. Established in 1951, the firm specializes in asset-based loans and factoring, offering services such as invoice factoring, revolving lines of credit, and equipment term loans. Gibraltar Business Capital caters to companies facing financial challenges, including those with limited operating history, negative cash flow, or fluctuating sales. The company collaborates closely with business owners, advisors, and financial sponsors to deliver tailored capital solutions that address specific needs, facilitating growth and stability. Its flexible and accessible funding alternatives serve as a critical resource in today's dynamic marketplace, ensuring businesses can navigate financial hurdles effectively.